TY - JOUR
AU - Brown, Nancy J.
AB - Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans Annis Marney, Siri Kunchakarra, Loretta Byrne, Nancy J. Brown Abstract—Dipeptidyl peptidase-IV inhibitors improve glucose homeostasis in type 2 diabetics by inhibiting degradation of the incretin hormones. Dipeptidyl peptidase-IV inhibition also prevents the breakdown of the vasoconstrictor neuropeptide Y and, when angiotensin-converting enzyme (ACE) is inhibited, substance P. This study tested the hypothesis that dipeptidyl peptidase-IV inhibition would enhance the blood pressure response to acute ACE inhibition. Subjects with the metabolic syndrome were treated with 0 mg of enalapril (n
9), 5 mg of enalapril (n
8), or 10 mg enalapril (n
7) after treatment with sitagliptin (100 mg/day for 5 days and matching placebo for 5 days) in a randomized, cross-over fashion. Sitagliptin decreased serum dipeptidyl peptidase-IV activity (13.081.45 versus 30.281.76 nmol/mL/min during placebo; P
0.001) and fasting blood glucose. Enalapril decreased ACE activity in a dose-dependent manner (P0.001). Sitagliptin lowered blood pressure during enalapril (0 mg; P
0.02) and augmented the hypotensive response to 5 mg of enalapril (P
0.05). In contrast, sitagliptin attenuated the hypotensive response to 10 mg of enalapril (P
0.02). During sitagliptin, but not during placebo, 10 mg of enalapril significantly increased heart rate and plasma norepinephrine concentrations. 
TI - Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
JF - Hypertension
DO - 10.1161/HYPERTENSIONAHA.110.156554
DA - 2010-10-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/interactive-hemodynamic-effects-of-dipeptidyl-peptidase-iv-inhibition-fUIgR0VlvY
SP - 728
EP - 733
VL - 56
IS - 4
DP - DeepDyve
ER -